Selected research
Industry Research
T Cell Antigen Gp39 Industry Research Report 2026
Market perspective
The global T Cell Antigen Gp39 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for T Cell Antigen Gp39 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for T Cell Antigen Gp39 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of T Cell Antigen Gp39 include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global T Cell Antigen Gp39 market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
T Cell Antigen Gp39 Market by Company
Biogen, Inc.
XL-protein GmbH
Targovax AS
MedImmune, LLC
Juno Therapeutics Inc.
ImmuNext, Inc.
eTheRNA Immunotherapies NV
Bristol-Myers Squibb Company
T Cell Antigen Gp39 Segment by Type
ECI-006
Hepatitis B Vaccine
ISF-35
INX-021
Others
T Cell Antigen Gp39 Segment by Application
Graft Versus Host Disease
Panceratic Cancer
Breast Cancer
Bladder Cancer
Others
T Cell Antigen Gp39 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Antigen Gp39 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of T Cell Antigen Gp39 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Antigen Gp39.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of T Cell Antigen Gp39 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of T Cell Antigen Gp39 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of T Cell Antigen Gp39 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ECI-006
- Hepatitis B Vaccine
- ISF-35
- INX-021
- Others
Applications
- Graft Versus Host Disease
- Panceratic Cancer
- Breast Cancer
- Bladder Cancer
- Others
Companies covered
- Biogen, Inc.
- XL-protein GmbH
- Targovax AS
- MedImmune, LLC
- Juno Therapeutics Inc.
- ImmuNext, Inc.
- eTheRNA Immunotherapies NV
- Bristol-Myers Squibb Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global T Cell Antigen Gp39 Market Size (2021-2032)
- 2.2.2 Global T Cell Antigen Gp39 Sales (2021-2032)
- 2.2.3 Global T Cell Antigen Gp39 Market Average Price (2021-2032)
- 2.3 T Cell Antigen Gp39 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ECI-006
- 2.3.3 Hepatitis B Vaccine
- 2.3.4 ISF-35
- 2.3.5 INX-021
- 2.3.6 Others
- 2.4 T Cell Antigen Gp39 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Graft Versus Host Disease
- 2.4.3 Panceratic Cancer
- 2.4.4 Breast Cancer
- 2.4.5 Bladder Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global T Cell Antigen Gp39 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global T Cell Antigen Gp39 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global T Cell Antigen Gp39 Revenue of Manufacturers (2021-2026)
- 3.4 Global T Cell Antigen Gp39 Average Price by Manufacturers (2021-2026)
- 3.5 Global T Cell Antigen Gp39 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of T Cell Antigen Gp39, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of T Cell Antigen Gp39, Product Type & Application
- 3.8 Global Manufacturers of T Cell Antigen Gp39, Established Date
- 3.9 Global T Cell Antigen Gp39 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biogen, Inc.
- 4.1.1 Biogen, Inc. Company Information
- 4.1.2 Biogen, Inc. Business Overview
- 4.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biogen, Inc. T Cell Antigen Gp39 Product Portfolio
- 4.1.5 Biogen, Inc. Recent Developments
- 4.2 XL-protein GmbH
- 4.2.1 XL-protein GmbH Company Information
- 4.2.2 XL-protein GmbH Business Overview
- 4.2.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 XL-protein GmbH T Cell Antigen Gp39 Product Portfolio
- 4.2.5 XL-protein GmbH Recent Developments
- 4.3 Targovax AS
- 4.3.1 Targovax AS Company Information
- 4.3.2 Targovax AS Business Overview
- 4.3.3 Targovax AS T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Targovax AS T Cell Antigen Gp39 Product Portfolio
- 4.3.5 Targovax AS Recent Developments
- 4.4 MedImmune, LLC
- 4.4.1 MedImmune, LLC Company Information
- 4.4.2 MedImmune, LLC Business Overview
- 4.4.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MedImmune, LLC T Cell Antigen Gp39 Product Portfolio
- 4.4.5 MedImmune, LLC Recent Developments
- 4.5 Juno Therapeutics Inc.
- 4.5.1 Juno Therapeutics Inc. Company Information
- 4.5.2 Juno Therapeutics Inc. Business Overview
- 4.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio
- 4.5.5 Juno Therapeutics Inc. Recent Developments
- 4.6 ImmuNext, Inc.
- 4.6.1 ImmuNext, Inc. Company Information
- 4.6.2 ImmuNext, Inc. Business Overview
- 4.6.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio
- 4.6.5 ImmuNext, Inc. Recent Developments
- 4.7 eTheRNA Immunotherapies NV
- 4.7.1 eTheRNA Immunotherapies NV Company Information
- 4.7.2 eTheRNA Immunotherapies NV Business Overview
- 4.7.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio
- 4.7.5 eTheRNA Immunotherapies NV Recent Developments
- 4.8 Bristol-Myers Squibb Company
- 4.8.1 Bristol-Myers Squibb Company Company Information
- 4.8.2 Bristol-Myers Squibb Company Business Overview
- 4.8.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio
- 4.8.5 Bristol-Myers Squibb Company Recent Developments
5 Global T Cell Antigen Gp39 Market Scenario by Region
- 5.1 Global T Cell Antigen Gp39 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global T Cell Antigen Gp39 Sales by Region: 2021-2032
- 5.2.1 Global T Cell Antigen Gp39 Sales by Region: 2021-2026
- 5.2.2 Global T Cell Antigen Gp39 Sales by Region: 2027-2032
- 5.3 Global T Cell Antigen Gp39 Revenue by Region: 2021-2032
- 5.3.1 Global T Cell Antigen Gp39 Revenue by Region: 2021-2026
- 5.3.2 Global T Cell Antigen Gp39 Revenue by Region: 2027-2032
- 5.4 North America T Cell Antigen Gp39 Market Facts & Figures by Country
- 5.4.1 North America T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America T Cell Antigen Gp39 Sales by Country (2021-2032)
- 5.4.3 North America T Cell Antigen Gp39 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe T Cell Antigen Gp39 Market Facts & Figures by Country
- 5.5.1 Europe T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe T Cell Antigen Gp39 Sales by Country (2021-2032)
- 5.5.3 Europe T Cell Antigen Gp39 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific T Cell Antigen Gp39 Market Facts & Figures by Country
- 5.6.1 Asia Pacific T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific T Cell Antigen Gp39 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific T Cell Antigen Gp39 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America T Cell Antigen Gp39 Market Facts & Figures by Country
- 5.7.1 South America T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America T Cell Antigen Gp39 Sales by Country (2021-2032)
- 5.7.3 South America T Cell Antigen Gp39 Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa T Cell Antigen Gp39 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa T Cell Antigen Gp39 Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global T Cell Antigen Gp39 Sales by Type (2021-2032)
- 6.1.1 Global T Cell Antigen Gp39 Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global T Cell Antigen Gp39 Sales Market Share by Type (2021-2032)
- 6.2 Global T Cell Antigen Gp39 Revenue by Type (2021-2032)
- 6.2.1 Global T Cell Antigen Gp39 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global T Cell Antigen Gp39 Revenue Market Share by Type (2021-2032)
- 6.3 Global T Cell Antigen Gp39 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global T Cell Antigen Gp39 Sales by Application (2021-2032)
- 7.1.1 Global T Cell Antigen Gp39 Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global T Cell Antigen Gp39 Sales Market Share by Application (2021-2032)
- 7.2 Global T Cell Antigen Gp39 Revenue by Application (2021-2032)
- 7.2.1 Global T Cell Antigen Gp39 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global T Cell Antigen Gp39 Revenue Market Share by Application (2021-2032)
- 7.3 Global T Cell Antigen Gp39 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 T Cell Antigen Gp39 Value Chain Analysis
- 8.1.1 T Cell Antigen Gp39 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 T Cell Antigen Gp39 Production Mode & Process
- 8.2 T Cell Antigen Gp39 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 T Cell Antigen Gp39 Distributors
- 8.2.3 T Cell Antigen Gp39 Customers
9 Global T Cell Antigen Gp39 Analyzing Market Dynamics
- 9.1 T Cell Antigen Gp39 Industry Trends
- 9.2 T Cell Antigen Gp39 Industry Drivers
- 9.3 T Cell Antigen Gp39 Industry Opportunities and Challenges
- 9.4 T Cell Antigen Gp39 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst